

January 23, 2026

To: All Concerned Parties

Solasia Pharma K.K. (Code 4597, TSE, Growth)
Representative: Yoshihiro Arai, President & CEO
Contact: Toshio Miyashita, CFO
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

Notice of License Agreement with MAAB for Sancuso® Rights in China Region

Solasia Pharma K.K. (head office: Tokyo Japan; hereinafter “the Company”) announces that, as part of restructuring the sales framework for its product Sancuso® in the China region (mainland China, Hong Kong, Macau and Taiwan) (Chinese name: 善可舒; development code: SP-01; hereinafter “Sancuso”), the Company has concluded a license agreement (hereinafter, “this Agreement”) with MAAB Pharma Limited (head office: Auckland, New Zealand; Managing Director: Alex Lou; hereinafter “MAAB”) as of today concerning exclusive marketing and manufacturing rights in the applicable territories.

Sancuso is a transdermal delivery formulation containing the 5-HT3 receptor antagonist granisetron as the active ingredient, designed to prevent the onset of chemotherapy-induced nausea and vomiting (CINV). It is designed to deliver the active ingredient continuously by a 7-day patch, and is a pharmaceutical product intended to help relieve the burden on patients who have difficulty taking antiemetic agents orally and on outpatients receiving chemotherapy.

Currently, Sancuso is commercialized in mainland China under a license agreement between the Company and Lee’s Pharmaceutical Holdings Limited (hereinafter “Lees”), which has a contract term ending at the end of 2026, and following the expiration of that agreement sales activities are scheduled to be transferred to MAAB. MAAB also plans to begin preparations for local production in China to reduce product costs.

Solasia Pharma KK, President & CEO, Yoshihiro Arai Comment

“The MAAB group has a strong network in the Chinese pharmaceutical industry and owns pharmaceutical manufacturing sites within China. Taking this Sancuso collaboration as an opportunity, we intend to make effective use of the MAAB group as a partner in our China business strategy.”

Under this Agreement, the Company will receive instalment contract payments from MAAB, to be paid according to the progress of the business transfer, and, after commencement of local production in China, would receive sales royalties. The impact of this Agreement on the Company’s financial results will be disclosed within the contractual framework as and when instalment contract payments are received.

End

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to Solasia and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of Solasia. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting Solasia’s actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. The information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information regarding pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. Solasia does not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.